Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CyBorD vs PAD in newly diagnosed multiple myeloma
NCT02362165Phase 3Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2015
- Primary completion
- Apr 2018
- Modality
- Modified Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cyclophosphamide, bortezomib and dexamethasone in multiple myeloma (MM), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
cyclophosphamidebortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02362165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02362165.